Fertility preservation access varies for AYA women with cancer

Clinical and sociodemographic factors significantly impact fertility preservation access for female adolescents and young adults with cancer.
A systematic review showed that as low as 9% or as high as 75% of patients have fertility preservation discussions with their clinicians, and receipt can vary from less than 1% to 70%.
Age, race, treatment, malignancy type, education and income had a significant effect on whether patients had discussions, consultations or completed preservation.
“People think fertility preservation completion is what equitable care looks like,” Marcela Algave, PhD, MPhil,

Orthobiologics registry needs vertifiable data

Few areas of orthopedic practice have grown faster and with thinner evidence than orthobiologics. Platelet-rich plasma has moved from the periphery of sports medicine to our offices as patients now ask for it by name.
In December 2025, the American Academy of Orthopaedic Surgeons announced the AAOS Orthobiologics Registry, developed with support from the American Orthopaedic Society for Sports Medicine, Arthroscopy Association of North America and Biologic Association. Leadership of the effort has framed the key objective to be separating science from hope.
The registry’s published

Michael Greger, MD: ‘Single swaps’ make a difference in nutrition

Clinicians should look for supporting evidence when answering questions about the latest nutrition trends or providing dietary recommendations, according to Michael Greger, MD, FACLM.
“You don’t want to change your clinical practice based on one study,” Greger said during a Healio Community webinar. “We want overwhelming evidence of benefit before we recommend it.”
In the webinar, Michelle Tollefson, MD, FACLM, an OB/GYN and professor in the department of health professions at Metropolitan State University of Denver, spoke with Greger, a founding member and fellow

Tirzepatide reduces heart risks in real-world setting

Tirzepatide reduced risk for major adverse cardiovascular events among adults with type 2 diabetes and established atherosclerotic cardiovascular disease, according to real-world data published in The BMJ.
As Healio previously reported, the SURPASS-CVOT trial found tirzepatide (Mounjaro, Eli Lilly) conferred a similar reduction in risk for CV events as dulaglutide (Trulicity, Eli Lilly) among adults with type 2 diabetes and atherosclerotic CVD. In a new study using data from two national claims databases in the U.S., researchers compared CV outcomes among adults using tirzepatide with those

Speaker: Integrative medicine gives patients ‘another option’

FORT LAUDERDALE, Fla. — Adding certain herbs and improved nutrition to Western medicine can have myriad benefits for patients with rheumatic and autoimmune conditions, said a presenter at the Rheumatology Nurses Society Annual Conference.
“Integrative medicine is about giving the patients another option,” Iris Zink, MSN, RN, ANP-BC, a rheumatology nurse practioner and co-owner of Pine Hollow Partners in East Lansing, Michigan, told Healio. “Many patients are scared of pharmaceuticals and western medicine since COVID.”
Zink said her clinic offers patients Western